HC Wainwright Issues Negative Estimate for GPCR Earnings

Key Points

• HC Wainwright materially cut near‑term and multi‑year EPS forecasts for Structure Therapeutics, lowering Q1 2026 to ($0.43) (from ($0.30)) and trimming FY2026 to ($1.72) and FY2027–FY2030, signaling expectations of deeper losses and increased uncertainty.
• Despite the revisions, HC Wainwright kept a Buy rating and a $114 price target; the stock traded near $63.13 after the company posted a quarterly EPS miss of ($0.49) vs. consensus ($0.35), and the analyst consensus remains a Moderate Buy with an average target around $107.90.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - HC Wainwright decreased their Q1 2026 earnings per share estimates for Structure Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.43) per share for the quarter, down from their previous estimate of ($0.30). HC Wainwright currently has a "Buy" rating and a $114.00 price target on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics' Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.72) EPS, FY2027 earnings at ($2.34) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at ($2.54) EPS and FY2030 earnings at ($2.28) EPS.

A number of other research analysts have also issued reports on the company. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a "buy" rating in a report on Thursday, December 11th. Citigroup reaffirmed an "outperform" rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Wall Street Zen upgraded shares of Structure Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Tuesday, January 20th. Finally, Citizens Jmp dropped their target price on Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating on the stock in a report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $107.90.

Structure Therapeutics Trading Up 0.2%

Shares of NASDAQ:GPCR opened at $63.13 on Thursday. The company's 50 day moving average is $75.10 and its two-hundred day moving average is $47.65. The company has a market cap of $4.46 billion, a PE ratio of -79.91 and a beta of -1.80. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming bought a new position in shares of Structure Therapeutics in the second quarter valued at approximately $28,000. EverSource Wealth Advisors LLC boosted its stake in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock valued at $30,000 after acquiring an additional 901 shares during the last quarter. CWM LLC boosted its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company's stock worth $33,000 after acquiring an additional 125 shares during the last quarter. Assetmark Inc. raised its stake in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after buying an additional 820 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company's stock valued at $92,000 after purchasing an additional 994 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Key Structure Therapeutics News

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: HC Wainwright (and coverage reported by other outlets) maintains a Buy rating and a $114 price target, signaling continued analyst conviction in Structure’s pipeline/value despite forecast cuts. Read More.
• Neutral Sentiment: The firm’s valuation backdrop is mixed: market cap ~ $4.46B, negative P/E (losses), a 50‑day moving average above the current price and a 200‑day below — investors are weighing momentum and longer‑term recovery potential. Read More.
• Negative Sentiment: HC Wainwright materially lowered near‑term quarterly EPS forecasts to roughly ($0.43)–($0.44) for Q1–Q4 2026 and cut FY2026 to ($1.72) (previously ~$($1.20)), signaling a weaker earnings trajectory than previously expected; that downward revision is a headwind for the stock. Read More.
• Negative Sentiment: HC Wainwright also trimmed FY2027–FY2030 estimates (FY2027 to ($2.34), FY2028 to ($2.45), FY2029 to ($2.54), FY2030 to ($2.28)), implying the analyst now expects deeper losses farther out — this increases uncertainty around future profitability and potential dilution/financing needs. Read More.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.